The role of anticholinergics in chronic obstructive pulmonary disease

被引:100
作者
Barnes, PJ [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Thorac Med, Natl Heart & Lung Inst, London SW3 6LY, England
关键词
D O I
10.1016/j.amjmed.2004.10.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anticholinergics are the bronchodilators of choice in the management of chronic obstructive pulmonary disease (COPD). They work by blocking muscarinic receptors in airway smooth muscle. Cholinergic tone appears to be the only reversible component of COPD. With the discovery of different muscarinic receptor subtypes, the development of m ore selective anticholinergics is possible. A major advance in this therapeutic area has been the discovery. of tiotropium bromide, which has kinetic selectivity for M-3 receptors as well as a duration of action of >24 hours. Once-daily administration of tiotropium is Well tolerated-and has shown significant advantages over ipratropium bromide, given 4 times daily, in the control of COPID.
引用
收藏
页码:24S / 32S
页数:9
相关论文
共 66 条
[11]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456
[12]   A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease [J].
Casaburi, R ;
Mahler, DA ;
Jones, PW ;
Wanner, A ;
San Pedro, G ;
ZuWallack, RL ;
Menjoge, SS ;
Serby, CW ;
Witek, T .
EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) :217-224
[13]   The spirometric efficacy of once-daily dosing with tiotropium in stable COPD - A 13-week multicenter trial [J].
Casaburi, R ;
Briggs, DD ;
Donohue, JF ;
Serby, CW ;
Menjoge, SS ;
Witek, TJ .
CHEST, 2000, 118 (05) :1294-1302
[14]   Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity [J].
Costello, RW ;
Jacoby, DB ;
Fryer, AD .
THORAX, 1998, 53 (07) :613-618
[15]   Tiotropium (Spiriva™):: Mechanistical considerations and clinical profile in obstructive lung disease [J].
Disse, B ;
Speck, GA ;
Rominger, KL ;
Witek, TJ ;
Hammer, R .
LIFE SCIENCES, 1999, 64 (6-7) :457-464
[16]   BA 679 BR, A NOVEL LONG-ACTING ANTICHOLINERGIC BRONCHODILATOR [J].
DISSE, B ;
REICHL, R ;
SPECK, G ;
TRAUNECKER, W ;
ROMINGER, KL ;
HAMMER, R .
LIFE SCIENCES, 1993, 52 (5-6) :537-544
[17]   Antimuscarinic treatment for lung diseases - From research to clinical practice [J].
Disse, B .
LIFE SCIENCES, 2001, 68 (22-23) :2557-2564
[18]  
Eglen RM, 1996, PHARMACOL REV, V48, P531
[19]   Muscarinic receptor ligands and their therapeutic potential [J].
Eglen, RM ;
Choppin, A ;
Dillon, MP ;
Hegde, S .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) :426-432
[20]   Perturbed equilibrium of myosin binding in airway smooth muscle and its implications in bronchospasm [J].
Fredberg, JJ ;
Inouye, DS ;
Mijailovich, SM ;
Butler, JP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) :959-967